GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GT Biopharma Inc (NAS:GTBP) » Definitions » Gross Profit

GTBP (GT Biopharma) Gross Profit : $0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is GT Biopharma Gross Profit?

GT Biopharma's gross profit for the three months ended in Jun. 2024 was $0.00 Mil. GT Biopharma's gross profit for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. GT Biopharma's gross profit for the three months ended in Jun. 2024 was $0.00 Mil. GT Biopharma's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. Therefore, GT Biopharma's Gross Margin % for the quarter that ended in Jun. 2024 was N/A%.

GT Biopharma had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of GT Biopharma was 6.56%. The lowest was 6.56%. And the median was 6.56%.


GT Biopharma Gross Profit Historical Data

The historical data trend for GT Biopharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GT Biopharma Gross Profit Chart

GT Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GT Biopharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GT Biopharma's Gross Profit

For the Biotechnology subindustry, GT Biopharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GT Biopharma's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where GT Biopharma's Gross Profit falls into.



GT Biopharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

GT Biopharma's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

GT Biopharma's Gross Profit for the quarter that ended in Jun. 2024 is calculated as

Gross Profit (Q: Jun. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

GT Biopharma's Gross Margin % for the quarter that ended in Jun. 2024 is calculated as

Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


GT Biopharma  (NAS:GTBP) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

GT Biopharma had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage


GT Biopharma Gross Profit Related Terms

Thank you for viewing the detailed overview of GT Biopharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


GT Biopharma Business Description

Traded in Other Exchanges
N/A
Address
8000 Marina Boulevard, Suite 100, Brisbane, CA, USA, 94005
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Executives
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Michael Martin Breen director, officer: Exec. Chair. and Interim CEO LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU
Manu Ohri officer: CFO & Secretary 2355 MAIN STREET, SUITE 120, IRVINE CA 92614
Bruce Wendel director 70 ELEVEN O'CLOCK ROAD, WESTON CT 06883
Gregory Berk officer: Pres. of R&D, CMO HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080
Shrotriya Rajesh C Md director 157 TECHNOLOGY DRIVE, IRVINE CA 92618
Alan Louis Urban director 1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404
Gavin Choy officer: Acting Chief Financial Officer 8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005
Steven W Weldon director, officer: CFO 7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835
Shawn Cross director, officer: Chief Executive Officer 1825 K STREET SUITE 510, WASHINGTON DC 20006
Raymond W. Urbanski officer: Chief Medical Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Kathleen Clarence-smith director, 10 percent owner, officer: CEO 1623 31ST STREET NW, WASHINGTON DC 20007
Mark J Silverman 10 percent owner 224 22ND ST., SANTA MONICA CA 90402
Bristol Capital Llc 10 percent owner
Bristol Investment Fund Ltd 10 percent owner 89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205